HK Innoen fire extinguishing team Ko Jong-baek, Kim Dong-wook, Kim Tae-jin PM interview
Compared to existing drugs, the effect appears faster and has excellent durability
[현대건강신문=여혜숙 기자] “K-CAP is a product that leads the P-CAP market, and we will continue to lead the generational change in the treatment of gastric acid-related diseases.”
HK Innoen’s digestive team is a new drug ‘K-CAB (ingredient: tegoprazan)’ that represents Korea’s representative P-CAB (Potassium-Competitive Acid Blocker), a treatment for gastroesophageal reflux disease. He expressed his ambition to lead.
K-Cap was released as the 30th new drug in Korea in 2019, and in less than two years, it surpassed 100 billion won in cumulative sales, raising the status of a blockbuster domestic new drug.
K-Cab, a new drug of the new series (P-CAB), has a faster medicinal effect compared to the existing PPI (Proton Pump Inhibitor) series products, can be taken before or after a meal, and has excellent longevity of the drug. It has the advantage of restraining it.
K-Cap currently has four indications: erosive, non-erosive, gastric ulcer, and Helicobacter pylori eradication. Clinical trials aiming to add indications for ‘prevention of gastric and duodenal ulcers related to NSAID administration’ by 2024. is in progress
In addition, the Ministry of Food and Drug Safety has applied for a change of product approval for the indication of ‘maintenance therapy after treatment of erosive gastroesophageal reflux disease’ and is under review by the Ministry of Food and Drug Safety. looking forward to
PM Koh Jong-baek introduced, “In the case of a change in dosage form, an orally disintegrating tablet was released in May of this year, and an injectable dosage form is being developed in China.”
HK Innoen’s ‘K-Cap Orally Disintegrating Tablet’ is a formulation that melts in the mouth and helps patients who have difficulty swallowing tablets or those who have difficulty drinking water. In addition, peppermint flavor was added to minimize the discomfort caused by the taste.
GoPM said, “By introducing an orally disintegrating tablet three years after the launch of K-Cap, we expect that customized prescriptions taking into account the characteristics of patients will become more active in the future. We will elevate our competitiveness to the fullest,” he said.
In fact, HK Innoen plans to further solidify the position of ‘K-Cap’, leading the generational change from PPI to P-CAP through various clinical trials.
PM Dongwook Kim said, “There are 63 clinical trials that have been conducted or are currently in progress, including SIT, IIT, observational studies, and PMS. In addition, 30 cases were registered, and the number of K-CAB-administered patients who participated in the 5 indications developed so far from phase 1 to phase 3 clinical trials was approximately 1,400, and the number of volunteers participating in other studies was approximately 1,500, estimated to be approximately 2,900. will be,” he said.
In addition, he explained, “More than 2 million patients have been prescribed K-CAB every year since its launch.”
For example, a drug interaction test with atorvastatin, a representative drug of the statin class metabolized by CYP3A4, which is frequently prescribed in cardiology or endocrinology departments, or a pharmacodynamics comparison test with existing PPI or P-CAB to reach pH 4 or higher In addition to a study comparing the duration of treatment, a study evaluating whether symptoms disappear quickly due to rapid onset of drug effect, an on-demand study considering the characteristics of a drug, a clinical trial for preventing GI bleeding after ESD treatment, or various HP eradication regimens research is in progress.
Thanks to these efforts, K-Cap recorded 109.6 billion won of outpatient prescriptions last year, up 43.9% from the previous year, and ranked first in the domestic peptic ulcer solvent market for two consecutive years following 2020.
It is also accelerating its global expansion. HK Innoen, which is about to be approved and released in major countries in Southeast Asia and Central and South America, starting with its recent launch in China, plans to make this year the first year of its entry into the overseas market and foster K-cap as a global blockbuster new drug.
A total of 34 countries have signed export contracts for K-Cap’s technology and finished products so far, and K-Cap’s global debut is expected to begin in earnest this year.
PM Taejin Kim said, “Korea’s representative P-CAB new drug, K-Cab, is leading the generational change from PPI to P-CAB. The goal is to establish itself as a First Choice treatment option that helps patients and medical staff with related symptoms through its features.”